Subscribe Us

header ads

Global Chronic Idiopathic Constipation Market

Global Chronic Idiopathic Constipation Market size was valued US$ XX Bn. in 2019 and the total revenue is expected to grow at 6.7% through 2019 to 2027, reaching nearly US$ 3.12 Bn.



Global Chronic Idiopathic Constipation Market

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Chronic Idiopathic Constipation i.e. CIC is called as the chronic existence of these symptoms (constipation). It is known as idiopathic because the cause of this type of constipation is unknown and it is not initiated by an underlying disease or medication.

In the U.S. as many as 35 Mn. adults may suffer from CIC. The numbers may be greater as all patients do not seek medical help. Studies have shown that only approximately 12% with the disorder seek medical help. Now, yet, 40% of patients with chronic idiopathic constipation are under medicine. It is slightly further common in women around 56% and adults above the age of 35 years around 84%. The MMR report analyzes various factors which have been driving the global CIC market in the past. The report also showcases the opportunities available in the chronic idiopathic constipation market which may act as a future driver for the global market. Such as growing clinical trials and approval of drug applicants by pharmaceutical players to fulfill unmet medical needs of the CIC treatment is a major factor fueling the market growth over 2019-2027. On the flip side, a restricted operating revenue opportunity for R&D of targeted therapies by various pharmaceuticals is acting as a challenging factor for the growth of global chronic idiopathic constipation market.

The report covers the segments in the chronic idiopathic constipation market such as route of administration, drug class, and distribution channel. Based on drug class, the laxatives segment is expected to grow at the highest XX% CAGR during the forecast period. Laxatives can aid with softening stool and improving the regularity of bowel actions. Fiber supplements have a related effect.

By route of administration, the oral segment dominated the chronic idiopathic constipation market, with market size of US$ XX Mn. in 2019 and to reach US$ XX Mn. by 2027, with a CAGR of XX.05%. As patients prefer taking oral drugs as they are invasive, convenient, and need no different training to take drugs.

The research study includes the profiles of leading companies operating in the chronic idiopathic constipation market globally. Such as, in 2018, Mallinckrodt Company, a worldwide specialty pharmaceutical company, announced the acquisition of Sucampo Pharmaceuticals Company, a biopharmaceutical company. The acquisition assets contain its FDA accepted blockbuster drug Amitiza i.e. lubiprostone for the treatment of CIC in adults, IBS-C (irritable bowel syndrome with constipation).

North America is expected to continue to hold the largest XX% share in the chronic idiopathic constipation market. Higher awareness amongst physicians and patient population considerably contribute the CIS market growth in the USA. Initial commercialization of the drug in the United States also adds up to the high demand of the drug in this market. However, a gradual overview of Linaclotide in other emerging markets will facilitate market growth in the APAC market. India, China, Japan, and Australia are the major countrywide markets that are likely to give the highest revenue contributions to the APAC chronic idiopathic constipation market.

The objective of the report is to present a comprehensive analysis of the Global Chronic Idiopathic Constipation Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Chronic Idiopathic Constipation Market dynamics, structure by analyzing the market segments and projects the Global Chronic Idiopathic Constipation Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Chronic Idiopathic Constipation Market make the report investor’s guide.
Scope of the Global Chronic Idiopathic Constipation Market

Global Chronic Idiopathic Constipation Market, by Drug Class

• Emollients
• Laxatives
• Bulk-forming Agents
• Osmotic Agents
• Other Drug Class
Global Chronic Idiopathic Constipation Market, by Route of Administration

• Oral
• Parental
Global Chronic Idiopathic Constipation Market, by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Chronic Idiopathic Constipation Market, by Region

• Asia Pacific
 India
 China
 Japan
 South Korea
 Australia
 Indonesia
 Malaysia
 Vietnam
 Rest of Asia
• North America
 U.S.
 Canada
• Europe
 U.K
 Germany
 France
 Russia
 Spain
 Italy
 Sweden
• South America
 Mexico
 Brazil
 Rest of South America
• Middle East & Africa
 GCC
 South Africa
 Rest of MEA
Key players operating in the Global Chronic Idiopathic Constipation Market

Actavis
• Chugai Pharmaceutical
• Ferring International Center S.A.
• Synergy Pharmaceuticals
• Pfizer
• GlaxoSmithKline
• Roche Holding AG
• Sanofi
• Bayer AG
• Salix Pharmaceuticals Ltd
• Sucampo Pharmaceuticals Inc
• Ironwood Pharmaceuticals
• Progenics Pharmaceuticals
• Merck Sharp & Dohme
• Theravance Biopharma Inc

Post a Comment

0 Comments